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Objective. Anorexia nervosa is a condition of reduced hemodynamic load, characterized by varying degrees of cardiac remodelling,
only in part related to reduced body mass; the mechanism for such variability, as well as its clinical signiﬁcance, remains unknown.
Aim of the study was to assess the possible inﬂuence of a great number of clinical, biochemical, and endocrine factors on
cardiovascular parameters in restrictive anorexia nervosa. Method. Twenty-ﬁve female patients hospitalized for restrictive anorexia
nervosa underwent extensive cardiovascular, clinical, and biochemical evaluation. Results. Height-adjusted and cardiac workload-
matched left ventricular mass was signiﬁcantly related to several endocrine parameters, blood pressure, and vasoreactivity. On
multivariateanalysis,IGF/GHratioandsystolicbloodpressureweretheonlyindependentpredictorsofheight-adjustedventricular
mass (adj-R2 = 0.585; P = 0.001); when matching for cardiac workload, left ventricular mass was independently predicted only by
GH and FT3 levels. All eﬀects were independent of patient’s weight and BMI. Conclusions. Indices of endocrine impairment seem
to be the most relevant determinants of left ventricular hypotrophy in anorectic patients, apparently independent of reduced
hemodynamic load and BMI. In particular, IGF/GH ratio and FT3 seem to particularly aﬀect left ventricular mass in this
population.
1.Determinantsof CardiacRemodelling in
Restrictive AnorexiaNervosa
Anorexia nervosa (AN) is a common psychiatric disorder,
characterized by weight loss, protein-energy malnutrition,
and severe organic complications leading to increased long-
term morbidity and mortality; despite the prevalence and
severity of this condition, clinicians still rely mainly on
BMI and clinical assessment in the risk stratiﬁcation of AN
patients [1]. Most of the organic abnormalities described in
anorectic patients are traditionally regarded to as adaptive
mechanisms of protection against chronic starvation [2].
Several studies have explored the cardiac ﬁndings in the
setting of AN: frequent morphological features include
mitral valve prolapse, mild pericardial eﬀusion, and a
reduced left ventricular mass [3–8]. Although the latter
could be interpreted as an adaptive response to the reduced
hemodynamic needs during AN, researchers agree that ven-
tricular remodelling appears to be extremely variable among
patients, apparently independent from the extent of weight
loss and other traditional markers of malnourishment.
To date, no study has tried to speciﬁcally identify the
determinants of such variability in left ventricular mass and
cardiovascular pattern of AN patients.
2. Methods
2.1. Subjects. Twenty-ﬁve women with restrictive-type AN
were enrolled during hospitalization at the local psychiatric
institution. Diagnosis of AN was conﬁrmed by two inde-
pendent consultant psychiatrists following current DSM-
IV criteria [9]. Binging and/or purging behaviours were
speciﬁcally excluded in all patients. Patients with previously
diagnosed cardiac and/or endocrine disease were excluded.2 ISRN Endocrinology
All patients reported a sedentary lifestyle and no cardiac
symptoms at rest or upon eﬀort.
Most patients underwent both cardiovascular assessment
and blood sampling before the beginning of any therapeutic
intervention; in the minority of patients enrolled during
urgent hospitalization, blood sampling occurred before
treatment, while cardiovascular assessment was delayed
to two to three days after start of refeeding. The study
conformed to the Declaration of Helsinki. Patients and their
families gave informed consent to the procedures.
2.2. Measurements. Patient’s weight and body composition
were studied by means of a footpad bioelectrical impedance
analyzer (Tanita TBF-215 device, Tanita Corp., Japan) by
using manufacturer-provided formulas.
Blood pressure was measured after ten minutes of rest in
a sitting position, using a standard adult or pediatric arm-
cuﬀ, according to the subject’s arm circumference.
A complete echocardiographic examination was per-
formed using a commercially available system (Aplio CV,
Toshiba Corporation, Otawara, Japan). Left ventricular mass
(LVM) was estimated using M-Mode measurements of left
ventricular wall thickness and diameters, following the rec-
ommendationsoftheAmericanSocietyofEchocardiography
[10]; the estimate of myocardial mass was then normalized
by body surface area (LVMi) and height in meters to the
power of 2.7 (LVMh) [6].
In order to take into account the reduced hemodynamic
load of this particular population, weight-independent,
height- and stroke-work-predicted left ventricular mass was
calculated for each subject by means of a validated formula,
as previously described by others in a similar popula-
tion [7]; LVM% was then deﬁned as follows: (observed
LVM/predicted LVM)∗100. LVM% was accordingly deﬁned
as “inadequate” using reference values from the same study
(observed LVM less than 73% of predicted LVM).
Endothelial-dependent dilation was assessed with the
ﬂow-mediated dilation test (FMD) of the brachial artery
with Doppler echocardiography, according to the recom-
mendations of the International Brachial Artery Reactivity
Task Force [11]. The upper arm was occluded for 5min
resulting in a reactive hyperemia after the release of the cuﬀ,
and the increased shear stress led to endothelial-mediated
vasodilatation.FMDwasmeasuredwiththesameultrasound
scanner with a 7.5MHz linear transducer (Toshiba PLT-
704AT), soon after the echocardiographic exam.
Cardiac evaluation also included 24-hour ambulatory
ECG monitoring, with subsequent oﬄine analysis of heart
rate variability (HRV) both in frequency and time domain,
as described elsewhere [12].
For each instrumental technique, the same investigator
performed and analyzed all assessments.
Venus blood samples were collected in the morning, after
an overnight fast (14hrs), for measurement of insulin-like
growth factor 1 (IGF-1), growth hormone (GH), cortisol,
ACTH, thyrotropin (TSH), FT3,F T 4, prolactin, and DHEAS.
Serum GH was assayed with an immunoradiometric assay
IRMA method and serum IGF-I with an RIA using a mono-
clonal antibody after acid-ethanol extraction. Evaluation of
plasmaTSHlevelswasperformedbyanultrasensitiveimmu-
noradiometric assay with a detection limit of 0.05mU/L.
Serums FT4 and FT3 were measured using the Lisophase
Kits (Bouty). All samples were also analyzed for common
biochemistry, electrolytes, and complete blood count.
2.3. Statistical Analysis. Data are expressed as means ± SDs.
Analysis was performed using SPSS version 12 (SPSS Inc.,
Chicago,IL).Log-transformedvalueswereusedforstatistical
analysis of the ratio of IGF-1 to GH (log IGF1/GH), as
already described by others [13]. Two-sided unpaired t-test
was used for diﬀerence between subgroups. The Pearson (r)
correlationmethodwasusedforcorrelationanalysisbetween
continuous variables. A P<0.05 was considered signiﬁ-
cant. Linear regression analysis was performed to identify
cofactors predictive of lower LVMh and LVM%; signiﬁcantly
associated dependent variables were then analyzed in a
stepwise multiple regression model.
3. Results
Patient characteristics, echocardiographic, electrocardio-
graphic, vasoreactivity, biochemical, and endocrine parame-
ters are shown in Table 1. Our population exhibited very low
absolute values of LVM, although only 7 out of 25 patients
(28%) showed “inadequately” low LVM% when matched for
height and cardiac workload, using the same cut-oﬀsa si n
Romano et al. [7].
Subgroup analysis comparing patients with “inade-
quately” low LVM% (see Section 2) only showed signiﬁcant
diﬀerences in terms of GH, logIGF/GH, and FT3 levels (see
Table 2). No diﬀerence was found regarding BMI and other
anthropometric and biochemical variables
Correlation analysis revealed strong, signiﬁcant corre-
lations between logIGF-1/GH and both LVMi, LVMh, and
LVM% (resp., r=0.638, r = 0.706, and r = 0.618; P = 0.001
for LVMh; Figure 1(a)). Other signiﬁcant correlations were
found for LVMh with SBP, FMD values, and GH levels (resp.,
r = 0.603; r = 0.489; r =− 0,54; P<0.05 for all).
Among hormonal parameters, only IGF-1 (r = 0.630;
P = 0.005; Figure 1(b)) and cortisol (r =− 0.579; P = 0.01)
were signiﬁcantly correlated with the patient’s BMI, while no
signiﬁcance was found for GH, logIGF1/GH, DHEAS, and
thyroid hormones.
Linear regression analysis was performed looking for
predictors of LVMh among all explored variables. Covariates
found signiﬁcant at univariate analysis were SBP, FMD, GH,
logIGF-1/GH(P<0.05forall).Thesewereusedformultiple,
backward,stepwiselinearregression;insuchanalysislogIGF-
1/GH, and SBP revealed as the only independent predictors
of LVMh and LVMi (adj-R2 = 0.585; P = 0.001).
A further analysis was performed using LVM% as the
dependent variable; signiﬁcant univariate cofactors were
BMI, GH levels, logIGF-1/GH and FT3. On backward step-
wise multiple regression analysis, reduced FT3, and elevated
GH levels remained the only independent predictors of low
LVM% (adj-R2 = 0.384; P<0.02).
No signiﬁcant correlation was found between HRV para-
meters, body composition and any of the hormones
measured.ISRN Endocrinology 3
Table 1: Patient characteristics, echocardiographic, endocrine, and electrocardiographic parameters (n = 25).
Age (years) 24 ±9 Tryglycerides (mg/dL) 70 ± 18
SBP (mmHg) 92 ±8 Hemoglobin (g/dL) 11,9 ±1,5
DBP(mmHg) 72 ±6 GH (ng/mL) 11.7 ± 16.6
HR (bpm) 58 ±10 IGF-1 (ng/mL) 127 ±53
Weight (kg) 39 ±5l o g I G F - 1 / G H 1 .26 ± 0.60
BMI 15.2 ±2.0 Cortisol (ng/mL) 168 ±36
Fat mass (kg) 5.2 ±2.0T S H ( µU/mL) 2.0 ± 0.8
Lean mass (kg) 32.7 ±4.0F T 3 ( p g / m L ) 1 .8 ± 0.5
RWT 0.35 ±0.06 FT4 (ng/dL) 0.9 ± 0.1
LVM (g) 75 ±19 Prolactin (ng/mL) 9.9 ± 7.4
LVMi (g/m2)5 7 ±14 DHEAS (µg/dL) 105 ±46
LVMh (g/m2.7)2 2 ±6F M D ( % ) 1 3 .9 ±5.0
LVM% (%) 83 ±18 Mean 24-hour HR (bpm) 68 ± 10
Inadequate LVM (n) 7/25 24-hour SDNN (msec) 177 ±36
E/A 2.1 ±0.8 24-hour SDANN (msec) 161 ±33
LVEF (%) 63 ±9 VLF (ms2/Hz) 36 ±8
Albumin (g/dL) 4.4 ±0.6L F ( m s 2/Hz) 31 ± 11
Cholesterol (mg/dL) 158 ±30 HF (ms2/Hz) 22 ±9
Data shown as Mean ± SD. SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; RWT: relative wall thickness; E/A: ratio of the E wave
to A wave velocities of transmitral ﬂow; LVEF: left ventricular ejection fraction; SDANN: SD of the averages of NN intervals in all 5-minute segments; SDNN:
SD of all NN intervals; VLF: very-low frequency power; LF: low frequency power; HF: high frequency power.
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4. Discussion
This is the ﬁrst study to systematically address the determi-
nants of cardiac alterations in AN. The patterns of cardiac
and endocrine alterations in our patients substantially
resemble those reported in previous studies. Although IGF-
1 and cortisol correlated well with body weight and BMI,
not all of the variability in IGF1:GH ratio and thyroid
hormone levels seems attributable to body composition
alone; this phenomenon has recently been described in a
larger report, and it might account for some of the clinical
and prognostic discrepancy among patients with similar
BMIs [14]: individuals with similar BMIs may show very
diﬀerent degrees of organic compromise, as indicated by
heterogeneous endocrine and cardiac phenotypes, and such
diﬀerences might aﬀect the patient’s prognosis.
The present results suggest a strong association between
high GH levels, low IGF-1, low FT3, and reduced LVM in
anorectic patients. Interestingly, this association seems to act
independent of body weight, BMI, left ventricular afterload
and peripheral markers of malnutrition. It is therefore likely
that the very low values of LVM observed in some emaciated
patients do not exclusively reﬂect reduced hemodynamic
requirements due to low body mass, as elsewhere postulated,
but also mirror a more complex alteration of the metabolic
and endocrine status of the whole organism.4 ISRN Endocrinology
Table 2: Comparison between patients with adequate and inade-
quate left ventricular mass.
Adequate LVM
(n = 18)
Inadequate LVM
(n = 7) P =
Age (years) 23 ±62 6 ±14 0.4
HR (bpm) 60 ±11 54 ±10 0.2
SBP (mmHg) 93 ±89 0 ±70 . 4
DBP (mmHg) 62 ±86 4 ±50 . 7
BMI 15.3 ±1.61 3 .9 ±2.00 . 0 8
Albumin (g/dL) 4.5 ±0.54 .1 ±0.80 . 2
Hemoglobin
(g/dL) 12.3 ±21 1 .7 ±30 . 4
GH (ng/mL) 7.1 ±6.52 3 .9 ±25 0.03∗
IGF-1 (ng/mL) 136.4 ±50.9 103.6 ±57 0.2
logIGF1/GH 1.4 ±0.50 .8 ±0.70 . 0 2 ∗
FT3 (pg/mL) 2.1 ±0.31 .3 ±0.3 <0.001∗
FT4 (ng/dL) 0.9 ±0.10 .9 ±0.20 . 7
TSH (µU/mL) 2.1 ±0.51 .9 ±0.40 . 6
Cortisol
(ng/mL) 161 ±32 189 ±44 0.1
FMD (%) 14.0 ±5.81 3 .5 ±2.50 . 8
Mean 24-hour
HR (bpm) 71 ±86 4 ±60 . 0 7
Age at onset
(years) 15.3 ±2.01 5 .2 ±1.60 . 8
Disease
duration (years) 7.7 ±5.61 1 .0 ±12.80 . 4
Note. See Table 1. ∗P<0.05 at unpaired t-test.
Actually, only a subgroup of patients in our cohort
showed “inadequately” low LVM (about 30% of the sub-
jects); this is in line with the most important studies in
the ﬁeld to date, and our ﬁndings propose an intriguing
explanation of this heterogeneity [7, 8]. These patients
showed a worse overall status, with a trend towards lower
BMI and longer history of disease; though, the only signif-
icant diﬀerences between the two groups were in terms of
endocrine markers. It is well known that GH, FT3 and IGF-1
exert potent physiologic trophic eﬀects on the myocardium,
both in health and disease; it is therefore reasonable that
only those patients who develop a multiple endocrine
dysfunction with peripheral resistance to GH and low FT3
levels besides weight loss also show inadequately low cardiac
mass.Althoughitiscommonsensetoconceivetheendocrine
changes of anorexia as adaptive responses to starvation,
such changes have recently been demonstrated to predict
high short-term probability of severe organic complications,
in a fashion independent of BMI and other “traditional”
markers [14]; our study conﬁrms that endocrine and cardiac
abnormalities in these populations are, to a certain extent,
unrelated to body weight and BMI. Hence, a low cardiac
mass could represent a useful supplemental clinical marker
of systemic malnourishment. Of note, one previous study
described concordant reversal of both cardiac hypotrophy
and low IGF-1 levels after weight gain in a few adolescent
AN patients [15].
Ourﬁndingsalsoputforwardagainthequestionwhether
the alterations in the somatotropic axis are among the
main actors of the “metabolic blockade” typical of the most
compromised AN patients, in whom muscle catabolism
can continue despite aggressive nutritional support. Many
groups have hypothesized a beneﬁcial eﬀect of GH and IGF-
1 administration on appetite, muscle metabolism, and bone
mass density in AN [16]. The studies brought equivocal
results; at least for IGF-1 therapy, this was also due to
short treatment duration and/or low doses employed, aimed
mainly at observing an improvement in bone density or
surrogates of bone turnover [17, 18]. Further studies with
higher doses are being designed by us and others.
5. Study Limitations
The present study is mainly limited by the small number
of subjects examined; however, both cardiac and endocrine
ﬁndings in our patients were reasonably compatible with
those of previous works. The absence of a control group
was intentional, as all of the explored parameters had
already been individually studied in similar populations.
Growth hormone status is best assessed by means of multiple
measurements throughout the day and overnight; this was
not performed due to logistical reasons in this particular
population. Of course, no causative relationship can be
asserted between GH/IGF1 imbalance, FT3 levels and cardiac
hypotrophy; similarly, no prognostic eﬀect can be asserted
from our data alone. Larger, longitudinal follow-up studies
in similar populations will be of help in this regard.
6. Conclusions
Our results conﬁrm that left ventricular remodelling is
very variable in AN and show that parameters of GH-
resistance and low FT3 levels seem to be the best predictors
of low left ventricular mass beyond hemodynamic load
and BMI. Therefore, cardiac phenotype seems a valuable
candidate parameter for prognostic stratiﬁcation in this
patient population.
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